Neurobehavioral Effects of Sulfated CCK Octapeptides in Zebrafish: Insights from Intracerebroventricular Administration

Study Background and Research Question

Cholecystokinin (CCK) is a well-characterized brain–gut peptide with diverse physiological roles, ranging from modulation of feeding and gastrointestinal function to regulation of anxiety and nociceptive behaviors. Among its molecular forms, the sulfated cholecystokinin octapeptide (CCK-8s) is particularly notable for its potent activity via G protein–coupled receptors CCK1R and CCK2R. While the anxiogenic or anxiolytic effects of CCK-8s have been explored in mammals and select teleosts, the neuroanatomical distribution and functional role of CCK-8s in zebrafish (Danio rerio) remained poorly characterized. The referenced study (paper) sought to clarify whether sulfated CCK-8 peptides, representing two molecular forms found in zebrafish, can modulate anxiety-like behavior when administered centrally, and to map their brain localization.

Key Innovation from the Reference Study

The central innovation of this work is the demonstration that both zebrafish CCKA-8s and CCKB-8s, when administered directly into the brain ventricles, induce robust anxiety-like behavioral responses in zebrafish. This not only establishes a functional role for CCK-8s in teleost neurobehavioral regulation but also provides direct evidence for the involvement of CCK receptor signaling in anxiety paradigms outside mammalian systems (paper). The study further identifies the specific neuroanatomical regions with CCK-like immunoreactivity, advancing the neuroethological relevance of zebrafish as a model organism.

Methods and Experimental Design Insights

The researchers employed a combination of neuroanatomical mapping and behavioral pharmacology:

• Immunohistochemistry: Brain sections of adult zebrafish were stained to localize CCK-like immunoreactivity, revealing prominent distributions in the ventral habenular nucleus, interpeduncular nucleus, and superior raphe.
• Synthetic Peptide Administration: Two synthetic, sulfated CCK-8 peptides (zfCCKA-8s and zfCCKB-8s) were synthesized to match the predicted zebrafish sequences.
• Intracerebroventricular (ICV) Injection: Peptides were administered directly into the brain at doses of 1, 5, and 10 pmol/g body weight. The methodology accounted for the small size of zebrafish, which historically presented a technical barrier for such studies (paper).
• Behavioral Assay: The preference test, exploiting the innate tendency of zebrafish to remain in the lower tank area under anxiogenic conditions, was used as a sensitive readout for anxiety-like behavior induction in zebrafish (paper).
• Pharmacological Validation: The CCK receptor antagonist proglumide was co-administered to confirm CCK receptor-mediated effects.

Core Findings and Why They Matter

• Both zfCCKA-8s and zfCCKB-8s, at 10 pmol/g BW, significantly reduced the time zebrafish spent in the upper tank area, mirroring the behavioral effects of the established anxiogenic agent FG-7142. The dose–response relationship was robust, with maximal behavioral effects at the highest tested dose (paper).
• Administration of proglumide, a broad-spectrum CCK receptor antagonist, attenuated these anxiogenic effects, directly implicating CCK receptor signaling in the observed behaviors.
• The neuroanatomical mapping showed that CCK-like immunoreactivity was particularly enriched in brain regions previously implicated in vertebrate anxiety circuits, supporting the physiological relevance of the findings.

This work positions zebrafish as a translational model for studying the neuromodulatory actions of CCK-8s, and highlights the evolutionary conservation of CCK receptor function across vertebrate taxa (paper).

Comparison with Existing Internal Articles

Several internal resources (e.g., Cholecystokinin Octapeptide Ammonium: Bridging Mechanistic Insights, Cholecystokinin Octapeptide Ammonium: Integrative Mechanisms) provide broader perspectives on the pleiotropic effects of cholecystokinin octapeptide ammonium (CCK-8 ammonium) in mammalian and non-mammalian systems. These articles emphasize CCK-8 ammonium’s roles in apoptosis inhibition, immune response modulation, and promotion of atrial natriuretic peptide secretion via well-mapped signaling axes (e.g., NOX4–PGC-1α–PPARα/γ–ANP). The referenced zebrafish study extends these mechanistic frameworks by directly demonstrating behavioral modulation—specifically, anxiety-like behavior induction in zebrafish—thus bridging molecular and systems-level outcomes in a vertebrate model. Unlike internal discussions, which focus more on biochemical workflow and signaling breadth, the present study delivers concrete behavioral and anatomical data in a non-mammalian context, reinforcing the translational versatility of the CCK-8 motif.

Limitations and Transferability

While the study robustly demonstrates the anxiogenic actions of zebrafish CCK-8s, several limitations are noted:

• The behavioral paradigm is limited to acute, ICV administration and immediate anxiety-like responses. Chronic effects or potential compensatory adaptations are not addressed.
• Only two molecular forms of CCK-8s were studied, and both were administered at relatively high doses compared to physiological peptide concentrations in vivo (paper).
• Mechanistic dissection of downstream signaling (e.g., involvement of specific β-arrestin pathways, NOX4, or PPARα/γ) was not performed in this model, although such pathways are well documented in mammalian systems (internal article).
• The direct translation of zebrafish behavioral endpoints to mammalian (or clinical) anxiety remains inferential, though the evolutionary conservation of CCK receptor signaling supports relevance.

Despite these constraints, the work provides a rigorous foundation for cross-species studies on neuropeptide function and anxiety modulation.

Protocol Parameters

• assay | ICV-induced anxiety-like behavior in zebrafish | 1–10 pmol/g body weight | Acute induction of anxiety-like response, validated via behavioral preference test | paper
• assay | Immunohistochemistry for CCK-like peptide | qualitative (regional localization) | Maps neuroanatomical targets of CCK action | paper
• assay | CCK receptor antagonist (proglumide) blockade | 200 pmol/g body weight | Confirms receptor-mediated effect | paper
• assay | In vitro modulation of apoptosis, immune signaling, and ANP secretion | 0.01–1 μmol/L | Supports molecular mechanism studies, especially in mammalian cells | product_spec
• assay | Chronic or repeated administration in zebrafish | not reported | Recommend pilot studies to assess long-term effects | workflow_recommendation

Research Support Resources

Researchers aiming to replicate or extend these findings can consider the use of Cholecystokinin octapeptide ammonium (SKU C8717), a rigorously characterized CCK-8 ammonium salt suitable for in vitro and in vivo studies of neuropeptide signaling, anxiety-like behavior induction, apoptosis inhibition, immune response modulation, and atrial natriuretic peptide secretion (source: product_spec). For detailed mechanistic and workflow guidance, see related internal resources such as the advanced discussion of zebrafish neurobehavioral models (internal article). As with all peptide reagents, strict adherence to validated storage and handling protocols is recommended to preserve bioactivity (source: product_spec).